18 September 2026
Aspen's turnaround hinges on filling its underused sterile manufacturing plants, as GLP-1 sales drive a share recovery.
9 September 2026
Aspen has abandoned local lenacapavir production, citing no guaranteed demand, and is backing Merck's alimatravir pill instead.
8 September 2026
Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.
22 August 2026
Pharmaceutical localisation talks target pricing reform, investment incentives, medicine security and stronger local manufacturing.
19 August 2026
The AIDS drug tender dispute deepens as the Health Department defends its R15.5bn HIV procurement process ahead of a September court hearing.
27 July 2026
Aspen HIV prevention pill licensing deal positions the SA manufacturer to supply lower-cost monthly PrEP across key African markets.
21 July 2026
Aspen Semaglutide Canada gains Health Canada approval, but API supply problems could delay the generic’s commercial launch.
10 July 2026
Aspen Chair Transition will see Ben Kruger replace Kuseni Dlamini as Aspen Pharmacare prepares for debt-free growth and new investment.
22 June 2026
Contraceptive shortages hit South Africa following Aspen's manufacturing issues, prompting alternatives for the public health sector.
15 May 2026
Discover the benefits of the Africa Vaccine Procurement Framework for vaccine manufacturing and demand aggregation in Africa.
8 May 2026
Aspen Insulin approval marks a milestone for diabetes care in South Africa, ensuring supply security with locally made insulin.
27 April 2026
Weight management spending in South Africa is rising fast as consumers pay for diet support, GLP-1 medicines and healthier food.